低分子量肝素的非抗凝活性-一篇评论
Ke Feng1, Kaixuan Wang1, Yu Zhou1
1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, 38 Tongyan Road, Jinnan District, Tianjin 300350, China.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2023
概括
低分子量肝素 (LMWHs) 为肝素提供更安全的替代品,副作用较少. 本综述强调了它们的多样性结构,制备方法以及对各种疾病的显著非抗凝效应.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 药物开发 药物开发
背景情况:
- 低分子量肝素 (LMWHs) 是一种肝素衍生物,其分子量为2000-8000 Da.
- 与未分离的肝素相比,LMWH提供了更好的安全性,降低了出血和肝素诱导的血小板缩的风险.
- 不同的制备方法导致不同的LMWH结构和生物活动.
研究的目的:
- 审查LMWH制备方法并比较其原则和优势.
- 专注于LMWH及其结合物的非抗凝药学作用.
- 总结LMWHs的临床应用和潜在用途.
主要方法:
- 对LMWH生产的化学和酶分离方法的审查.
- 分析各种LMWH结构及其由此产生的生物活动.
- 关于非抗凝效应的研究和临床研究的汇编.
主要成果:
- LMWHs表现出选择性活动和比肝素更少的副作用.
- 关键的非抗凝剂作用包括防止糖核流失,抗炎,抗病毒,抗纤维,抗血管,改善内皮功能.
- 在癌症,病毒性疾病,纤维状况和产科疾病的动物模型中,LMWH显示出有效性.
结论:
- LMWH具有显著的非抗凝性质,具有广泛的治疗潜力.
- 了解制备方法对于优化LMWH疗效至关重要.
- 对于各种疾病,LMWHs的进一步临床发展是有必要的.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552
Clot Retraction and Fibrinolysis
6.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.4K
Extrinsic and Intrinsic Pathways of Hemostasis
8.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.2K


